XORTX Therapeutics
XRTX
3 hedge funds and large institutions have $9.51K invested in XORTX Therapeutics in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
64% less capital invested
Capital invested by funds: $26.6K → $9.51K (-$17.1K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Clearstead Advisors
Cleveland,
Ohio
|
+$1.57K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$261 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$18.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Osaic Holdings
Scottsdale,
Arizona
| $6.23K | – | – | – |
|
|
CA
2
Clearstead Advisors
Cleveland,
Ohio
| $3K | +$1.57K | +6 | +100% |
|
3
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| $286 | – | – | – |
|
4
Bank of America
Charlotte,
North Carolina
| $1 | – | – | – |
|
|
5
Citadel Advisors
Miami,
Florida
| – | -$18.3K | -69 | Closed |
|
|
6
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$261 | +1 | New |
|
XRTX Hedge Fund Activity: Q3 2023 in Review
3 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q3 2023, worth a combined $9.51K — down 64% from $26.6K a quarter earlier.
Fund positioning in XRTX was balanced in Q3 2023: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Clearstead Advisors, adding an estimated $1.57K. The largest seller was Citadel Advisors, exiting entirely with an estimated $18.3K sold.
- 3 institutional investors held XORTX Therapeutics (XRTX) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $9.51K of XORTX Therapeutics stock for Q3 2023, down 64% quarter-over-quarter.
- 1 fund opened new XORTX Therapeutics positions in Q3 2023 and 1 closed out, a net change of 0 holders.
- The largest XORTX Therapeutics buyer in Q3 2023 was Clearstead Advisors, an estimated $1.57K added.
- The largest XORTX Therapeutics seller in Q3 2023 was Citadel Advisors, an estimated $18.3K sold.
Based on aggregated 13F filings for Q3 2023.